Godfrey, Laura http://orcid.org/0000-0002-6222-3563
Crump, Nicholas T. http://orcid.org/0000-0001-9610-6763
Thorne, Ross
Lau, I-Jun
Repapi, Emmanouela http://orcid.org/0000-0001-8085-0731
Dimou, Dimitra
Smith, Alastair L. http://orcid.org/0000-0001-6330-1407
Harman, Joe R. http://orcid.org/0000-0003-3668-1859
Telenius, Jelena M.
Oudelaar, A. Marieke http://orcid.org/0000-0002-4016-6158
Downes, Damien J.
Vyas, Paresh http://orcid.org/0000-0003-3931-0914
Hughes, Jim R. http://orcid.org/0000-0002-8955-7256
Milne, Thomas A. http://orcid.org/0000-0002-0413-4271
Funding for this research was provided by:
RCUK | Medical Research Council (MC_UU_12009/6, MC_UU_12009/6, MC_UU_12009/6, MC_UU_12009/6, MC_UU_12009, MC_UU_12009, MC_UU_12009)
RCUK | MRC | Medical Research Foundation (MC_UU_12009/6, MC_UU_12009/6, MC_UU_12009/6, MC_UU_12009/6, MC_UU_12009/6)
Wellcome Trust (106130/Z/14/Z)
Article History
Received: 14 August 2018
Accepted: 5 June 2019
First Online: 26 June 2019
Competing interests
: P.V. and T.A.M. are founding shareholders of Oxstem Oncology (OSO), a subsidiary company of OxStem Ltd. The other authors declare no competing interests.